E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Cutaneous T Cell Lymphoma |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 22.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10028483 |
E.1.2 | Term | Mycosis fungoides |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Characterize patients’ experienced treatment benefit of CD11301 gel a.Provide a patient-focused assessment of disease burden. b.Capture patients’ experience of the study treatment (what are the perceived benefits and risks of treatment, changes in patients’ daily life since baseline, unexpected treatment effects, patients’ treatment expectations, satisfaction and comparison to previous treatments). c.Explore patients’ perceptions of meaningful change from baseline (i.e., what constitutes a meaningful treatment effect, which aspects are most relevant and most meaningful to patients).
|
|
E.2.2 | Secondary objectives of the trial |
Explore patients’ experience with clinical trial participation and obtain patients’ insights into the operational aspects of the clinical trial (e.g., burden of visits, study procedures, etc.) to inform the design of future Phase 3 clinical trials with a view to increase their patient centricity. The telephone interview findings will also support the development of a comprehensive disease model to support a fit-for-purpose measurement strategy to assess meaningful treatment benefit of CD11301 gel in future clinical trials in CTCL.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Had participated or is currently participating in Galderma’s Phase 2 clinical trial of the CD11301 gel and has completed cycle 2 (week 24) or Patient has exited the study trial early due to patient request or clinician judgement 2. Able to remember experience with taking clinical trial treatment 3.Willing and able to participate in a 60-90 minute telephone interview 4.Able to understand, read, and speak native English (US) or German (Germany) sufficiently to participate in the interview 5. Willing and able to provide oral and written informed consent 6. Willing and consenting to be audio-recorded during the discussion.
|
|
E.4 | Principal exclusion criteria |
1. Hearing difficulty, visual impairment, acute psychopathology, or insufficient knowledge of English (US) or German (Germany) that, in the opinion of the investigator/interviewer, could interfere with patient ability to provide oral consent and written consent and complete an interview. 2. Not able to remember experience with taking clinical trial treatment in the opinion of the investigator.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
subject-reported concepts regarding disease burden and meaningful treatment benefit |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
after interview which takes place after patient has completed treatment |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
This qualitative research study will explore patients’ perspectives about disease burden and meaningful treatment benefit among a subset of patients with early stage CTCL who participate in the Phase 2 clinical trial of the CD11301 gel in the US and Germany. The telephone interview findings will also support the development of a comprehensive disease model to support a fit-for-purpose measurement strategy to assess meaningful treatment benefit of CD11301 gel in future clinical trials in CTCL.
|
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |